Low methylation marker levels among human papillomavirus‐vaccinated women with cervical high‐grade squamous intraepithelial lesions
Open Access
- 27 May 2024
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 155 (9) , 1549-1557
Abstract
Cervical cancer screening programs, including triage tests, need redesigning as human papillomavirus (HPV)‐vaccinated women are entering the programs. Methylation markers offer a potential solution to reduce false‐positive rates by identifying clinically relevant cervical lesions with progressive potential. In a nested case–control study, 9242 women who received the three‐dose HPV16/18‐vaccine at ages 12–15 or 18 in a community‐randomized trial were included. Subsequently, they were re‐randomized for either frequent or infrequent cervical cancer screening trials. Over a 15‐year post‐vaccination follow‐up until 2022, 17 high‐grade squamous intraepithelial lesion (HSIL) and 15 low‐grade (LSIL) cases were identified at the 25‐year screening round, alongside 371 age and community‐matched HPV16/18‐vaccinated controls. Methylation analyses were performed on cervical samples collected at age 25, preceding histologically confirmed LSIL or HSIL diagnoses. DNA methylation of viral (HPV16/18/31/33) and host‐cell genes (EPB41L3, FAM19A4, and miR124‐2) was measured, along with HPV‐genotyping. No HPV16/18 HSIL cases were observed. The predominant HPV‐genotypes were HPV52 (29.4%), HPV59/HPV51/HPV58 (each 23.5%), and HPV33 (17.7%). Methylation levels were generally low, with no significant differences in mean methylation levels of viral or host‐cell genes between the LSIL/HSIL and controls. However, a significant difference in methylation levels was found between HSIL cases and controls when considering a combination of viral genes and EPB41L3 (p value = .0001). HPV‐vaccinated women with HSIL had HPV infections with uncommon HPV types that very rarely cause cancer and displayed low methylation levels. Further investigation is warranted to understand the likely regressive nature of HSIL among HPV‐vaccinated women and its implications for management.Keywords
This publication has 30 references indexed in Scilit:
- Clinical performance of methylation as a biomarker for cervical carcinoma in situ and cancer diagnosis: A worldwide studyInternational Journal of Cancer, 2021
- Methylation markers FAM19A4 and miR124‐2 as triage strategy for primary human papillomavirus screen positive women: A large European multicenter studyInternational Journal of Cancer, 2020
- Baseline findings and safety of infrequent vs. frequent screening of human papillomavirus vaccinated womenInternational Journal of Cancer, 2019
- FAM19A4/miR124‐2 methylation in invasive cervical cancer: A retrospective cross‐sectional worldwide studyInternational Journal of Cancer, 2019
- Anxiety and distress following receipt of results from routine HPV primary testing in cervical screening: The psychological impact of primary screening (PIPS) studyInternational Journal of Cancer, 2019
- Impact of gender‐neutral or girls‐only vaccination against human papillomavirus—Results of a community‐randomized clinical trial (I)International Journal of Cancer, 2017
- Validation of a DNA methylation HPV triage classifier in a screening sampleInternational Journal of Cancer, 2016
- Methylation of viral and host genes and severity of cervical lesions associated with human papillomavirus type 16International Journal of Cancer, 2014
- A DNA methylation classifier of cervical precancer based on human papillomavirus and human genesInternational Journal of Cancer, 2014
- The 2001 Bethesda SystemTerminology for Reporting Results of Cervical CytologyJAMA, 2002